PreciseDx Continues Path to Commercial Launch: Secures Additional Funding and Announces New Leadership
Funding now totals over $43 million, strengthened leadership focused on a 2026 commercial launch of the OncoIntelligence™-driven, PreciseBreast™ NEW YORK, June 18, 2025 /PRNewswire/ — PreciseDx, the leading innovator behind PreciseBreast, a novel breast cancer diagnostic that is…